Epic Sciences
Epic Sciences is a private San Diego-based diagnostics company that has developed DefineMBC™, a blood-based liquid biopsy test for metastatic breast cancer, powered by a proprietary multi-omic single-cell sequencing platform serving oncology providers and pharmaceutical clinical trial sponsors.
- Company typePrivate
- Founded2008
- HeadquartersLa Jolla, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Epic Sciences does
Epic Sciences is a San Diego-based, privately held diagnostics company founded in 2008 that develops liquid biopsy solutions for oncology. Its flagship product, DefineMBC™, is a blood-based biopsy test designed to detect and characterize circulating tumor cells in metastatic breast cancer patients, providing a non-invasive alternative to surgical tissue biopsy for tumor analysis and treatment monitoring.
The company is built on a proprietary Multi-Omic Platform that combines single-cell sequencing with data analytics to enable comprehensive characterization of cancer from blood samples. This platform underpins both the DefineMBC clinical diagnostic and the company's pharmaceutical services offering, in which Epic Sciences partners with drug developers to support oncology clinical trials through patient stratification, biomarker discovery, and therapeutic monitoring. Over 700 patients have been tested through DefineMBC pilot programs.
Epic Sciences generates revenue through diagnostic testing services for healthcare providers (oncologists, cancer centers, hospital systems) and through subscription-style collaborations with pharmaceutical and biotech companies conducting oncology clinical trials. The company is in active commercial scaling mode following a $43 million Series F round in June 2022 and a $24 million Series G round in April 2023, with proceeds dedicated to expanding sales, marketing, and clinical evidence generation for DefineMBC. The company operates exclusively in the United States and employs 101–250 people.
Epic Sciences firmographics
Firmographics- Name
- Epic Sciences
- Legal name
- Epic Sciences
- Website
- https://epicsciences.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Epic Sciences is a private San Diego-based diagnostics company that has developed DefineMBC™, a blood-based liquid biopsy test for metastatic breast cancer, powered by a proprietary multi-omic single-cell sequencing platform serving oncology providers and pharmaceutical clinical trial sponsors.
- Ownership category
- akta.pro rank
Epic Sciences industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
- akta.pro secondary industries
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Reference & Esoteric Testing Laboratories (HLAFAMAJ)
Keywords
Where Epic Sciences is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Epic Sciences business model
Business model- GTM type
- B2B
- Offering type
- Services
Revenue model
- Diagnostic Testing Services: Revenue generated from commercializing DefineMBC blood-based biopsy tests for metastatic breast cancer diagnosis and monitoring
- Pharmaceutical Partnerships: Collaborations with drug development companies for liquid biopsy solutions supporting oncology clinical trials
Go-to-market motion1 record
Distribution channels2 records
Marketing channels1 record
Epic Sciences product offering
Product offeringCore offering
Epic Sciences develops and commercializes blood-based liquid biopsy diagnostic tests for oncology applications. The company's flagship product, DefineMBC, is a multi-omic test designed to inform treatment decisions for patients with metastatic breast cancer by analyzing circulating tumor cells and cell-free DNA from a single blood sample.
Product overview
Epic Sciences offers a diagnostics platform focused on liquid biopsy solutions for oncology. The core product is the DefineMBC™ blood-based biopsy test for metastatic breast cancer, powered by the company's Multi-Omic Platform that incorporates single-cell sequencing and advanced data analytics. The platform enables non-invasive cancer analysis from blood samples, supporting both clinical diagnostics and pharmaceutical drug development collaborations.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Over 700 patients successfully tested during pilot programs
- +1 more outcomes
Companies that use Epic Sciences
Customer profileNamed customers1 record
Segments2 records
Epic Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Epic Sciences partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
Epic Sciences competitors and assessment
Company assessmentDirect peers
- Guardant Health: Guardant Health is a leading liquid biopsy company offering oncology blood tests including Guardant360 for tumor profiling and Guardant Reveal for MRD — directly competing with Epic Sciences in the oncology liquid biopsy market with similar single-cell and ctDNA-based approaches serving oncologists and pharmaceutical companies.
- Natera: Natera offers Signatera, a tumor-informed MRD liquid biopsy test used for treatment monitoring in multiple solid tumor types including breast cancer, directly overlapping with Epic Sciences' DefineMBC in clinical use case, customer base (oncologists and pharma), and business model.
- Personalis: Personalis is a cancer genomics company developing liquid biopsy assays including NeXT Personal for MRD detection and tumor profiling. It competes directly with Epic Sciences in providing multi-omic, blood-based diagnostics for oncology treatment monitoring and pharma clinical trial support.
- NeoGenomics: NeoGenomics is a specialized oncology testing services company offering a broad menu of cancer-focused lab tests including liquid biopsy assays. It serves oncologists, hospitals, and pharma clients with diagnostic testing — overlapping significantly with Epic Sciences' clinical testing business model.
- ANGLE plc: ANGLE plc has developed the Parsortix system for harvesting circulating tumor cells from blood, directly competing with Epic Sciences' CTC-based approach. Both companies focus on CTC analysis for oncology diagnostics and pharma applications, with overlapping customer bases and technology positioning.
Broad incumbents
- Foundation Medicine: Foundation Medicine (acquired by Roche) provides comprehensive genomic profiling assays including FoundationOne Liquid CDx for blood-based tumor profiling. As a Roche-owned incumbent with broad pharma partnerships and established reimbursement, it represents a much larger competitor in the same oncology liquid biopsy space.
- Exact Sciences: Exact Sciences is a publicly-traded cancer diagnostics company best known for Cologuard, with an expanding oncology portfolio including liquid biopsy tests. It serves similar oncology and primary care customer segments with a much broader commercial footprint and menu.
- Bio-Techne: Bio-Techne provides reagents, instruments, and diagnostic tools used in oncology research and clinical diagnostics, including exosome-based and circulating biomarker products. While a much larger and broader life-sciences tools provider, it overlaps with Epic Sciences in enabling liquid biopsy and oncology diagnostic workflows.
Emerging players
- Adaptive Biotechnologies: Adaptive Biotechnologies applies immune sequencing and minimal residual disease detection in oncology (clonoSEQ for MRD in blood cancers). While primarily focused on hematologic malignancies, it represents an adjacent liquid biopsy / MRD player with similar pharma partnership and clinical diagnostic business models.
- Resolution Bioscience (Agilent): Resolution Bioscience, acquired by Agilent in 2021, developed a liquid biopsy platform for oncology cfDNA analysis with pharma partnership focus — closely comparable to Epic Sciences' liquid biopsy platform and pharma services business, now operating within Agilent's broader diagnostics portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Epic Sciences social profiles
Digital presenceEpic Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Epic Sciences leadership team
Management profileNumber of profiles
Epic Sciences funding detail
Funding detailFunding overview
Funding rounds8 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Epic Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Epic Sciences
What does Epic Sciences do?
Epic Sciences develops and commercializes blood-based liquid biopsy diagnostic tests for oncology applications. The company's flagship product, DefineMBC, is a multi-omic test designed to inform treatment decisions for patients with metastatic breast cancer by analyzing circulating tumor cells and cell-free DNA from a single blood sample.
Is Epic Sciences a public or private company?
Epic Sciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Epic Sciences founded?
Epic Sciences was founded in 2008. It employs 101 to 250 people.
Where is Epic Sciences based?
Epic Sciences is headquartered in La Jolla, United States, in the North America region.
How does Epic Sciences make money?
Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are pharmaceutical Partnerships.
Who are Epic Sciences's main competitors?
Direct peers on record are Guardant Health, Natera, Personalis, NeoGenomics and ANGLE plc. Broad incumbents are Foundation Medicine, Exact Sciences and Bio-Techne. Emerging players are Adaptive Biotechnologies and Resolution Bioscience (Agilent).
Does Epic Sciences have an API?
No public API is recorded for Epic Sciences.
What industry is Epic Sciences in?
Epic Sciences's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 8071.